



下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemECB-5083Cat. No.: HY-12861CAS No.: 1542705-92-9分式: CHNO分量: 413.47作靶點(diǎn): p97作通路: Cell Cycle/DNA Damage儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 100 mg/mL (241.86 mM)* means soluble, but s
2、aturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 2.4186 mL 12.0928 mL 24.1856 mL5 mM 0.4837 mL 2.4186 mL 4.8371 mL10 mM 0.2419 mL 1.2093 mL 2.4186 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲(chǔ)備液,并請注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?,配制前請先配制澄清的?chǔ)備液,再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性,體內(nèi)實(shí)驗(yàn)的作液,建議您現(xiàn)現(xiàn)配,當(dāng)天使;澄清的儲(chǔ)備液可
3、以根據(jù)儲(chǔ)存條件,適當(dāng)保存;以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占):1. 請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (6.05 mM); Clear solution2. 請依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (6.05 mM); Clear solution3. 請依序添加每種溶劑: 10% DMSO 90% corn oil1/3 Master of Small Molecu
4、les 您邊的抑制劑師www.MedChemESolubility: 2.5 mg/mL (6.05 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 CB-5083有效,選擇性和有服活性的 p97 抑制劑,IC50 值為 11 nM。IC50 & Target IC50: 11 nM (p97) 1體外研究 Treatment of tumor cells with CB-5083 leads to significant accumulation of markers associated with inhibitionof ubiquitinprotea
5、some system and endoplasmic reticulum-associated degradation functions, which inducesirresolvable proteotoxic stress and cell death 1體內(nèi)研究 In tumor bearing mice, oral administration of CB-5083 causes rapid accumulation of markers of the unfoldedprotein response and subsequently induces apoptosis lead
6、ing to sustained antitumor activity in in vivoxenograft models of both solid and hematological tumors. CB-5083 has been taken into phase 1 clinical trialsin patients with multiple myeloma and solid tumors 1.PROTOCOLKinase Assay 1 The ATPase assay is performed to determine the IC50 value. compounds (
7、CB-5083) are diluted in DMSOwith a 3-fold 10-point serial dilution starting at 10 M. The assay is done in a 384-well plate with each row asa single dilutionMCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 1 A549 and other tumor cell lines are
8、cultured according to ATCC guidelines. Cells are cultured in black orwhite, clear-bottomed, tissue culture-treated 384-well plates. Cells are treated with 10-point dose titration ofthe compound (CB-5083) in well duplicates. After a 72 h treatment, CellTiter-Glo is added to the white platesto measure
9、 cell viability 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice: Tumor-bearing mice are used to evaluate pharmacokinetics and pharmacodynamics effect andAdministration 1 antitumor activity. Both molecules (CB-5083 and compoud 69) are admin
10、istered orally as a suspension in0.5% methylcellulose aqueous suspensions at the fixed dose strength of 150 mg/kg; plasma and tumorsamples at multiple time points (2, 6, 16, and 24 h) are harvested for pharmacokinetics andpharmacodynamics analysis 1.MCE has not independently confirmed the accuracy o
11、f these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Leukemia. 2019 Jul;33(7):1675-1686.See more customer validations on HYPERLINK / www.MedChemE2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEREFERENCES1. Zhou HJ, et al. Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083). JMed Chem. 2015 Dec 24;58(24):9480-97.McePdfHeightCaution: Product has
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 醫(yī)院幼兒護(hù)理視頻課件
- 2024年智能人體秤項(xiàng)目投資申請報(bào)告代可行性研究報(bào)告
- 2024年硅系鐵合金資金籌措計(jì)劃書代可行性研究報(bào)告
- 落實(shí)檢察官登記管理辦法
- 2024年特種運(yùn)輸資金需求報(bào)告代可行性研究報(bào)告
- 融媒體教室使用管理辦法
- 衡水消防車管理辦法規(guī)定
- 行政執(zhí)法公務(wù)員管理辦法
- 裝配式住宅運(yùn)輸管理辦法
- 西安市疫情分級管理辦法
- 初中道德與法治學(xué)科教學(xué)經(jīng)驗(yàn)交流
- 工程測量、定位放線控制點(diǎn)復(fù)核記錄表
- 申辦出入境證件的函
- 七年級音樂作業(yè)
- 安全評估收費(fèi)指導(dǎo)意見
- 全過程工程造價(jià)咨詢服務(wù)實(shí)施方案
- DB34-T 4289-2022城鎮(zhèn)檢查井蓋安裝管理技術(shù)規(guī)程
- 江蘇建筑施工安全臺賬(正式版)
- 貴州省建筑與裝飾工程計(jì)價(jià)定額(2023版)
- 凈化磷酸裝置水聯(lián)動(dòng)試車方案
- 灰樹花白樺茸課件
評論
0/150
提交評論